Minerva Neurosciences Inc
Company Profile
Business description
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Contact
1500 District Avenue
BurlingtonMA01803
USAT: +1 617 600-7373
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
stocks
Tesla earnings: Shares fall as market focuses on uncertainty in near term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,317.20 | 26.50 | -0.28% |
| CAC 40 | 8,225.78 | 18.91 | 0.23% |
| DAX 40 | 24,207.79 | 56.66 | 0.23% |
| Dow JONES (US) | 46,734.61 | 144.20 | 0.31% |
| FTSE 100 | 9,578.57 | 63.57 | 0.67% |
| HKSE | 26,143.29 | 175.31 | 0.68% |
| NASDAQ | 22,941.80 | 201.40 | 0.89% |
| Nikkei 225 | 49,299.65 | 658.04 | 1.35% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,738.44 | 39.04 | 0.58% |
| S&P/ASX 200 | 9,019.00 | 25.20 | -0.28% |
| SSE Composite Index | 3,948.00 | 25.59 | 0.65% |